Microcap Ledger Ernexa Therapeutics Inc. $ERNA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- Shares outstanding
- 1,632,411 [10-Q 2026-08-06]
What the company doesAI summary of filing
Ernexa Therapeutics develops synthetic allogeneic induced mesenchymal stem cell (iMSC) product candidates using its iMSC technology platform for cell therapy applications. The company is a clinical-stage biopharmaceutical company with no revenue from product sales. The company's product candidates require FDA approval before commercialization, and their development faces challenges including manufacturing complexity, regulatory requirements, intellectual property uncertainties, and healthcare cost containment pressures. [10-K 2026-03-13]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$9.52M | −$6.42M | $5.03M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | −$14.08M | −$7.02M | $1.88M | [DEF 14A 2026-05-11] |
| FY ended Dec 2024 | $582.0K | −$44.54M | −$15.84M | $1.73M | [10-K 2026-03-13] |
- Quarterly cash burn
- −$3.21M
- Cash runway Estimate
- ~4.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 51,374,713 | [10-Q 2024-11-12] |
| 2025-03-10 | 52,244,929 | [10-K 2025-03-12] |
| 2025-05-07 | 62,363,763 | [10-Q 2025-05-07] |
| 2025-08-12 | 7,670,889 | [10-Q 2025-08-13] |
| 2025-11-07 | 7,848,889 | [10-Q 2025-11-07] |
| 2026-03-12 | 29,154,431 | [10-K 2026-03-13] |
| 2026-05-08 | 1,166,333 | [10-Q 2026-05-11] |
| 2026-08-06 | 1,632,411 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-03-16; declared effective 2026-03-30 [S-3 2026-03-16]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-03-20. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-03-20 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-03-20] |
| 2025-01-10 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-10] |
| 2025-01-03 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-03] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-02-10 | Cherington Charles | buy | 4,000,000 | $0.50 | [4 2026-02-17] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-16 | 8-K | Regulation FD disclosure |
| 2026-09-16 | 8-K | Director or officer change |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-02 | 8-K | Regulation FD disclosure |
| 2026-07-02 | 8-K | Shareholder vote results |
| 2026-06-26 | 8-K | Director or officer change |
| 2026-05-20 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-14 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-13 | 13G/A | Beneficial ownership report (5%+ holder) |
Alerts for $ERNA
Email me when Ernexa Therapeutics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.